In breast cancer cells, SHP-2 was found to enhance RTK activity such as EGFR and FGFR1 as well as downstream MAPK/ERK and PI3K-AKT signaling (Figure 3) [83]. This evidence concerns the gene EGFR and breast carcinoma.